Published in Br J Cancer on October 01, 1991
Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br J Cancer (2006) 3.23
Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci U S A (1994) 2.90
Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression. J Clin Invest (2005) 2.38
E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Am J Pathol (2000) 2.36
Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci U S A (1992) 2.07
A novel role of myosin VI in human prostate cancer. Am J Pathol (2006) 1.59
NF-kappaB activation in melanoma. Pigment Cell Res (2006) 1.55
Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma. Am J Pathol (1998) 1.50
Role of nuclear factor-kappa B in melanoma. Cancer Metastasis Rev (2005) 1.41
The bcl-2 proto-oncogene and the gastrointestinal epithelial tumor progression model. Am J Pathol (1995) 1.37
Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol (1993) 1.37
Gelatinase A activity directly modulates melanoma cell adhesion and spreading. EMBO J (1995) 1.34
Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis. Clin Cancer Res (2009) 1.34
msg1, a novel melanocyte-specific gene, encodes a nuclear protein and is associated with pigmentation. Proc Natl Acad Sci U S A (1996) 1.27
CD40 stimulation accelerates deletion of tumor-specific CD8(+) T cells in the absence of tumor-antigen vaccination. Proc Natl Acad Sci U S A (2001) 1.22
Interleukin 6: a fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression. Proc Natl Acad Sci U S A (1992) 1.20
Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): novel gene therapeutic for metastatic melanoma. Toxicol Appl Pharmacol (2006) 1.12
Regulation of Mel-CAM/MUC18 expression on melanocytes of different stages of tumor progression by normal keratinocytes. Am J Pathol (1994) 1.11
Effector CD4 and CD8 T cells and their role in the tumor microenvironment. Cancer Microenviron (2012) 1.05
Metabotropic glutamate receptors (mGlus) and cellular transformation. Neuropharmacology (2008) 1.02
Boolean network model for cancer pathways: predicting carcinogenesis and targeted therapy outcomes. PLoS One (2013) 1.01
Adaptive evolution of degrees and kinds of neoplastic transformation in cell culture. Proc Natl Acad Sci U S A (1992) 1.00
Expression of multi-cytokine resistance and multi-growth factor independence in advanced stage metastatic cancer. Malignant melanoma as a paradigm. Am J Pathol (1992) 1.00
Clonal T cell responses in tumor infiltrating lymphocytes from both regressive and progressive regions of primary human malignant melanoma. J Clin Invest (1996) 0.94
T-cell clonotypes in cancer. J Transl Med (2004) 0.91
Single-cell tumor dormancy model of uveal melanoma. Clin Exp Metastasis (2008) 0.88
Clostridial spores as live 'Trojan horse' vectors for cancer gene therapy: comparison with viral delivery systems. Genet Vaccines Ther (2008) 0.86
Incipient and overt stages of neoplastic transformation. Proc Natl Acad Sci U S A (1994) 0.85
Linkage of cutaneous malignant melanoma/dysplastic nevi to chromosome 9p, and evidence for genetic heterogeneity. Am J Hum Genet (1994) 0.84
Variant sublines of early-stage human melanomas selected for tumorigenicity in nude mice express a multicytokine-resistant phenotype. Am J Pathol (1994) 0.84
Epigenetic regulation of the TRAIL/Apo2L apoptotic pathway by histone deacetylase inhibitors: an attractive approach to bypass melanoma immunotherapy resistance. Am J Clin Exp Immunol (2013) 0.84
Matricellular proteins produced by melanocytes and melanomas: in search for functions. Cancer Microenviron (2008) 0.84
ACP best practice no 162. The histological reporting of melanoma. Association of Clinical Pathologists. J Clin Pathol (2000) 0.81
Induction of matrix metalloproteinase-1 (MMP-1) during epidermal invasion of the stroma in human skin organ culture: keratinocyte stimulation of fibroblast MMP-1 production. Br J Cancer (2001) 0.81
High rate of diversification and reversal among subclones of neoplastically transformed NIH 3T3 clones. Proc Natl Acad Sci U S A (1992) 0.80
CpG expedites regression of local and systemic tumors when combined with activatable nanodelivery. J Control Release (2015) 0.79
Phytochemicals for the Management of Melanoma. Mini Rev Med Chem (2016) 0.77
Smouldering malignant melanoma and metastatic dormancy: an update and review. Dermatol Res Pract (2011) 0.77
Moles and melanoma--new method in the madness. West J Med (1994) 0.75
Tumour and immune cell dynamics explain the PSA bounce after prostate cancer brachytherapy. Br J Cancer (2016) 0.75
A genetic model for colorectal tumorigenesis. Cell (1990) 44.37
Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med (1985) 7.22
How does the extracellular matrix direct gene expression? J Theor Biol (1982) 6.38
Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst (1989) 5.28
A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol (1984) 3.21
Influence of organ environment on the growth, selection, and metastasis of human colon carcinoma cells in nude mice. Cancer Res (1988) 2.67
Tumor cell instability, diversification, and progression to the metastatic phenotype: from oncogene to oncofetal expression. Cancer Res (1987) 2.24
Human cell hybrids: analysis of transformation and tumorigenicity. Science (1982) 2.16
Clonal adaptation during carcinogenesis. Biochem Pharmacol (1990) 2.04
Hepatocarcinogenesis: a dynamic cellular perspective. Lab Invest (1987) 1.82
Biology of tumor progression in human melanocytes. Lab Invest (1987) 1.61
The cellular basis of site-specific tumor metastasis. N Engl J Med (1990) 1.60
High risk of malignant melanoma in melanoma-prone families with dysplastic nevi. Ann Intern Med (1985) 1.51
Tumor progression in human malignant melanoma: five stages defined by their antigenic phenotypes. Int J Cancer (1987) 1.41
Cancer as a dynamic developmental disorder. Cancer Res (1985) 1.35
Anatomic markers of human premalignancy and risk of breast cancer. Cancer (1990) 1.35
Clonal dominance of primary tumours by metastatic cells: genetic analysis and biological implications. Cancer Surv (1988) 1.13
Spontaneous resolution of rectal polyps in patients with familial polyposis following abdominal colectomy and ileorectal anastomosis. Dis Colon Rectum (1988) 1.11
Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas. Cancer Res (1989) 1.07
Spindle cell and epithelioid cell nevi with atypia and metastasis (malignant Spitz nevus). Am J Surg Pathol (1989) 1.06
The pathogenesis of rat liver cancer caused by chemical carcinogens. Biochim Biophys Acta (1980) 1.05
Human nevocellular nevus cells are surrounded by basement membrane components. Immunohistologic studies of human nevus cells and melanocytes in vivo and in vitro. Lab Invest (1988) 1.04
Possible involvement of the chromosome region 10q24----q26 in early stages of melanocytic neoplasia. Cancer Genet Cytogenet (1988) 1.03
Screening and surveillance of patients at high risk for malignant melanoma result in detection of earlier disease. J Am Acad Dermatol (1990) 0.97
Human cutaneous malignant melanoma as a model for cancer. Cancer Metastasis Rev (1991) 0.94
Structure of basement membranes in malignant melanoma and nevocytic nevi. J Invest Dermatol (1989) 0.93
Chromosomal and molecular clues to tumor progression. Semin Oncol (1989) 0.93
Melanocytic atypia in dysplastic nevi. Immunohistochemical and cytophotometrical analysis. Cancer (1988) 0.91
Expression of Schwann cell characteristics in pigmented nevus. Immunohistochemical study using monoclonal antibody to Schwann cell associated antigen. Cancer (1988) 0.87
Melanosomal alterations in dysplastic melanocytic nevi. A quantitative, ultrastructural investigation. Cancer (1988) 0.87
Topobiology. Sci Am (1989) 0.85
Lymphatic invasion in Spitz nevi. Am J Surg Pathol (1985) 0.85
Biology of melanoma invasion and metastasis. Pigment Cell Res (1987) 0.83
The flow cytometry of melanocytic skin lesions. Br J Cancer (1988) 0.81
Lymphoid dependency and cutaneous melanoma. J Natl Cancer Inst (1990) 0.79
Aberrant differentiation in mouse skin carcinogenesis. IARC Sci Publ (1988) 0.78
Monoclonal antibody (AFH1) immunoreactive on morphologically abnormal basal melanocytes within dysplastic nevi, nevocellular nevus nests, and melanoma. J Invest Dermatol (1988) 0.78